News >

Acalabrutinib Improves PFS in Relapsed/Refractory CLL

Gina Columbus @ginacolumbusonc
Published: Tuesday, May 07, 2019

Jose Baselga, MD

José Baselga, MD

Acalabrutinib (Calquence) monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with the combination of rituximab (Rituxan) and either idelalisib (Zydelig) or bendamustine in patients with previously treated chronic lymphocytic leukemia (CLL), meeting the primary endpoint of the phase III ASCEND trial (NCT02970318).1



  1. Calquence Phase III ASCEND Trial Met Primary Endpoint at Interim Analysis in Relapsed or Refractory Chronic Lymphocytic Leukemia and Will Stop Early. AstraZeneca. Published May 7, 2019. Accessed May 7, 2019.
  2. Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in patients with relapsed/refractory (R/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL). Blood. 2018;132:4424. doi: 10.1182/blood-2018-99-110395.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication